Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05253872
Other study ID # Melacare v1.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 9, 2022
Est. completion date March 2028

Study information

Verified date June 2023
Source Herlev and Gentofte Hospital
Contact Sara M Hansen, MD
Phone +4538681296
Email sara.moelgaard.hansen@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.


Recruitment information / eligibility

Status Recruiting
Enrollment 378
Est. completion date March 2028
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ability to read and understand Danish language - Willing and able to give written informed consent - Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion Exclusion Criteria: - Advanced melanoma, clinical stages IIB, IIC, III, or IV - Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma) - History of melanoma skin cancer prior to the index diagnosis - Previous cancer, excluding non-melanoma skin cancer - Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function) - non-detection of sentinel node in IB and IIA patients

Study Design


Related Conditions & MeSH terms


Intervention

Other:
The MelaCare intervention
The primary principles applied will be: Meta-cognitive strategies and normalization of emotions Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination The intervention will include 4 components: An educational booklet Doctor consultation to ensure correct SSE skills and compliance to the protocol 3-5 sessions with a experienced and specially trained melanoma nurse Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae.

Locations

Country Name City State
Denmark Herlev and Gentofte Hospital Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
Herlev and Gentofte Hospital Danish Cancer Society

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fear of cancer recurrence The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. The primary outcome will be evaluated at approx. 6-8 months after randomization.
Primary Fear of cancer recurrence The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. The primary outcome will be evaluated at approx. 12 months follow-up
Primary Fear of cancer recurrence The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. The primary outcome will be evaluated at approx. 24 months follow-up
Secondary Evaluation of change from baseline in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity Depression score will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity Depression score will be evaluated at approx. 12 months follow-up
Secondary Evaluation of change from in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity Depression score will be evaluated at 24 months follow-up
Secondary Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. Anxiety score will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. Anxiety score will be evaluated at approx.12 months follow-up
Secondary Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. Anxiety score will be evaluated at approx. 24 months follow-up
Secondary Evaluation of change from baseline in distress score by the validated distress thermometer The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity Distress score will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in distress score by the validated distress thermometer The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity Distress score will be evaluated at approx.12 months follow-up
Secondary Evaluation of change from baseline in distress score by the validated distress thermometer The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity Distress score will be evaluated at approx. 24 months follow-up
Secondary Evaluation of change from baseline in activation score by the validated patient activation measure The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level Activation measure will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in activation score by the validated patient activation measure The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level Activation measure will be evaluated at approx.12 months follow-up
Secondary Evaluation of change from baseline in activation score by the validated patient activation measure The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level Activation measure will be evaluated at approx. 24 months follow-up
Secondary Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status Health status will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status Health status will be evaluated at approx.12 months follow-up
Secondary Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status Health status will be evaluated at approx. 24 months follow-up
Secondary Evaluation of change from baseline in work ability by the validated work ability index The work ability index has a scale from 7-49, where higher scores indicates better work ability. Work ability will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of change from baseline in work ability by the validated work ability index The work ability index has a scale from 7-49, where higher scores indicates better work ability. Work ability will be evaluated at approx.12 months follow-up
Secondary Evaluation of change from baseline in work ability by the validated work ability index The work ability index has a scale from 7-49, where higher scores indicates better work ability. Work ability will be evaluated at approx. 24 months follow-up
Secondary Evaluation of the time and costs spend by the patients getting to and from the follow-up visits The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits Time and costs spend will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of the time and costs spend by the patients getting to and from the follow-up visits The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits Time and costs spend will be evaluated at approx.12 months follow-up
Secondary Evaluation of the time and costs spend by the patients getting to and from the follow-up visits The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits Time and costs spend will be evaluated at approx. 24 months follow-up
Secondary Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. the number of extra clinical consultations with a doctor will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. the number of extra clinical consultations with a doctor will be evaluated at approx. 12 months follow-up
Secondary Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. the number of extra clinical consultations with a doctor will be evaluated at approx. 24 months follow-up
Secondary Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. the number of extra clinical consultations with a doctor will be evaluated at approx. 60 months follow-up
Secondary Evaluation of the number and characteristics of new primary melanomas and/or recurrences The investigator will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of the number and characteristics of new primary melanomas and/or recurrences The investigator will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx.12 months follow-up
Secondary Evaluation of the number and characteristics of new primary melanomas and/or recurrences The investigators will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 24 months follow-up
Secondary Evaluation of the number and characteristics of new primary melanomas and/or recurrences The investigators will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 60 months follow-up
Secondary Evaluation of time to diagnosis of a new primary melanoma and/or recurrence The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of time to diagnosis of a new primary melanoma and/or recurrence The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 12 months follow-up
Secondary Evaluation of time to diagnosis of a new primary melanoma and/or recurrence The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 24 months follow-up
Secondary Evaluation of time to diagnosis of a new primary melanoma and/or recurrence The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 60 months follow-up
Secondary Evaluation of health care costs of the new follow-up program compared to the current We will evaluate the health care cost of new follow-up program compared to the current. Data will be collected using national registries. Health care costs evaluation will be evaluated at approx. 60 months follow-up
Secondary Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. the number of extra scans will be evaluated at approx. 6-8 months after randomization.
Secondary Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. the number of extra scans will be evaluated at approx. 12 months follow-up
Secondary Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. the number of extra scans will be evaluated at approx. 24 months follow-up
Secondary Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. the number of extra scans will be evaluated at approx. 60 months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT04020809 - Neoadjuvant Atezolizumab in Cutaneous Melanoma Phase 1
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Completed NCT03628417 - Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases N/A
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT04830124 - Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 Phase 2
Recruiting NCT03699995 - MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma N/A
Recruiting NCT06319196 - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Phase 2
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04792463 - Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Completed NCT00679289 - Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma Phase 2
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Recruiting NCT04702854 - Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma N/A